Form 8-K

8-K — Theravance Biopharma, Inc.

Accession: 0001104659-26-093066

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0001583107

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622638d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622638d1_ex99-1.htm)

GRAPHIC (tm2622638d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622638d1_8k.htm · Sequence: 1

false

0001583107

2026-08-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported):

August 10, 2026

THERAVANCE

BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its

Charter)

Cayman Islands

001-36033

98-1226628

(State

or Other Jurisdiction of

(Commission

File Number)

(I.R.S.

Employer Identification

Incorporation)

Number)

c/o Theravance Biopharma US, LLC

901

Gateway Boulevard

South

San Francisco, CA 94080

(650)

808-6000

(Addresses, including zip code, and telephone

numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to

Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Ordinary

Share $0.00001 Par Value

TBPH

NASDAQ

Global Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company    ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On August 10, 2026, Theravance Biopharma, Inc. (the “Company”)

issued a press release regarding its financial results for the quarter ended June 30, 2026, and a business update. A copy of the press

release is furnished as Exhibit 99.1 to this Current Report.

The information in Item 2.02 and in Item 9.01 of this Current Report

on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of

the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities

of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities

Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press Release dated August 10, 2026

104

Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE BIOPHARMA, INC.

Date: August 10, 2026

By:

/s/ Aziz Sawaf

Aziz Sawaf

Senior Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622638d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Theravance Biopharma, Inc. Reports Second Quarter

2026 Financial Results and Provides Corporate Update

· Previously announced acquisition by Zymeworks expected to close in second half of 2026

· YUPELRI® Collaboration Revenue increased 11% year-over-year1,

from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage

· Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding

restructuring and transaction costs)

· Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone

payment2

· Quarter-end cash balance of $388 million and no debt

DUBLIN,

IRELAND – AUGUST 10, 2026 – Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”)

(NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026.

“During the second quarter, we entered

into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what

we believe achieves the greatest value for Theravance Biopharma shareholders,” said Rick E Winningham, Chief Executive Officer of

Theravance Biopharma. “At the same time, YUPELRI® delivered another strong quarter, underscoring the durability and

value of our core commercial asset and the continued execution of our collaboration with Viatris. We continued to execute well against

our restructuring plan and expect to close the Zymeworks transaction in the second half of 2026 subject to shareholder approval and customary

closing conditions.”

Pending Acquisition by Zymeworks

On June 29, 2026, following a comprehensive strategic alternatives

review process conducted by the Company's Strategic Review Committee and Board of Directors, Theravance Biopharma announced that it had

entered into a definitive agreement pursuant to which Zymeworks Inc. will acquire the Company for $17.00 per share in cash, plus a contingent

value right (CVR) entitling shareholders to 80% of net proceeds realized from any future license, divestiture or other monetization of

ampreloxetine over the next ten years.

The transaction is expected to close in the second half of 2026, subject

to approval by Theravance Biopharma shareholders and satisfaction of other customary closing conditions.

1 In the U.S., Viatris is leading the commercialization

of YUPELRI, and the Company co-promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to the Company).

2 Payment from Royalty Pharma (RP) will be triggered if

RP receives certain minimum royalty payments from GSK based on TRELEGY global net sales.

Page 1 of 9

Operational Highlights

YUPELRI® (revefenacin) inhalation solution, the

first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the U.S. for the maintenance

treatment of patients with chronic obstructive pulmonary disease (COPD):

· Quarterly U.S. net sales of $70.7 million, recognized by Viatris, in Q2 2026,

increasing 7% year-over-year (YoY) (Q2 2026 vs Q2 2025)1 driven by customer demand growth of 10% YoY (Q2 2026 vs Q2 2025).3

· Increased doses pulled through the hospital channel by 25% YoY (Q2 2026 vs

Q2 2025), reflecting another excellent quarter of growth.4

TRELEGY

GSK reported second quarter 2026 global net sales of approximately

$1.0 billion and year-to-date net sales of approximately $1.9 billion5:

· FY 2025 global net sales of approximately $3.9 billion triggered a $50M milestone

payment from Royalty Pharma, with cash received in February 2026.

· FY 2026 global net sales of ~$3.5 billion required to trigger an additional

$100M milestone payment from Royalty Pharma.

Organizational Restructuring Update

· Following the announcement of the Company’s Phase 3 CYPRESS results

in March 2026, Theravance Biopharma has made substantial progress on its organizational restructuring.

· As an indicator of this progress, operating expenses (excluding restructuring

and transaction costs) decreased 35% year-over-year in Q2 2026 compared to Q2 2025, with additional reductions expected in 2H 2026.

· The restructuring is expected to reduce operating expenses by approximately

60%, relative to 2025 actuals of $111.1 million. The full run-rate cost savings of approximately $70 million are expected to materialize

in the second half of 2026. This is expected to result in approximately $60 - $70 million of annualized cash flow (excluding restructuring

and transaction costs), with the benefit expected to be realized beginning in the second half of 2026.

Second Quarter Financial Results

· Revenue: Total revenue for the second quarter of 2026 was $20.7 million,

consisting entirely of Viatris collaboration revenue. Viatris collaboration revenue increased by $2.0 million, or 11%, in the second quarter

compared to the same period in 2025. The Viatris collaboration revenue represents amounts receivable from Viatris and comprises the Company’s

35% share of net sales of YUPELRI, as well as its proportionate amount of the total shared commercial costs incurred by the two companies.

The non-shared YUPELRI costs incurred by Theravance Biopharma are recorded within operating expenses. While Viatris records the total

net sales of YUPELRI within its financial statements, Theravance Biopharma’s implied 35% share of net sales of YUPELRI for the second

quarter of 2026 was $24.7 million which represented a 7% increase compared to the same period in 2025.

3 Source: Viatris

Customer Demand (Q2’26).

4 Source: IQVIA

DDD, HDS, VA and Non-Reporting Hospital through Jun ’26.

5 GSK-reported

Net Sales in USD.

Page 2 of 9

· Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were $4.7 million, compared to

$10.5 million in the same period in 2025. The reduction was driven by the corporate restructuring announced in March 2026 and the ongoing

wind-down of the CYPRESS clinical trial. Second quarter R&D expenses included total non-cash share-based compensation of $0.6 million.

· Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the second quarter of 2026 were $14.2 million,

compared to $18.4 million in the same period in 2025. The reduction was primarily driven by the corporate restructuring announced in March

2026. Second quarter SG&A expenses included total non-cash share-based compensation of $3.6 million.

· Restructuring Expenses: Restructuring expenses for the

second quarter of 2026 were $4.0 million and were comprised of severance costs and termination-related benefits. Cash restructuring expenses

were $2.2 million and non-cash restructuring expenses were $1.8 million.

· Transaction-Related Expenses: Transaction-related expenses

associated with the pending acquisition by Zymeworks were $6.1 million in the second quarter of 2026 and were related to legal and financial

advisory services.

· Share-Based Compensation: Total share-based compensation expenses

for the second quarter of 2026 were $6.0 million which included restructuring-related share-based compensation expenses. Excluding restructuring-related

expenses, share-based compensation was $4.1 million, compared to $4.5 million in the same period in 2025. Share-based compensation expenses

for the second quarter of 2026 consisted of $0.6 million for R&D, $3.6 million for SG&A, and $1.8 million related to the restructuring.

· Net Loss: Net loss was $5.9 million in the second quarter of 2026

compared to net income of $54.8 million in the same period in 2025. The second quarter of 2025 net income was primarily due to a $75.1

million net gain on contingent milestone and royalty assets (representing the sale of our remaining interest in TRELEGY royalties in June

2025).

Page 3 of 9

· Non-GAAP Net Income (Loss) from Operations6:

Non-GAAP net income from operations was $9.5 million in the second quarter of 2026 compared to a non-GAAP net loss from operations of

$4.2 million in the same period in 2025. See the section titled "Non-GAAP Financial Measures" for more information.

· Cash Position: Cash, cash equivalents and marketable securities totaled

$387.7 million as of June 30, 2026.

· Shares Outstanding: The Company had 51,890,754 ordinary shares outstanding

as of June 30, 2026.

Conference Call

Earnings results are being released via press release only. The Company

will not host a conference call or webcast to discuss quarterly results.

About Theravance Biopharma

Theravance Biopharma, Inc.’s focus is to

deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma

leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution

indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The Company is committed to creating/driving

shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE®

and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and

certain other countries).

YUPELRI® is a registered trademark of Viatris

Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective

owners.

6 Non-GAAP profit (loss) consists of GAAP net income (loss)

before taxes less (i) share-based compensation expense, (ii) non-cash interest expense, and (iii) non-recurring revenue and income (expense)

items. See the section titled "Non-GAAP Financial Measures" for more information.

Page 4 of 9

Forward-Looking Statements

This press release contains certain “forward-looking” statements

as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to

goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (the “Company”) intends such forward-looking

statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange

Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements

include statements relating to: the Company’s expectations regarding its future profitability, expenses and uses of cash, the Company’s

goals, designs, strategies, plans and objectives, future growth of YUPELRI sales and future royalty payments, the winddown of the Company’s

ampreloxetine program and the restructuring, the ability to provide value to shareholders, the Company’s regulatory strategies,

and contingent milestone payments due to the Company from the sale of the Company’s TRELEGY royalty interests. These statements

are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and

are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance

Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual

results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: the approval

of the Company’s shareholders for the proposed transaction, which may be delayed or may not be obtained, when the contingent consideration

under the CVR Agreement contemplated in connection with the proposed transaction will become payable, if at all, the risks inherent in

the drug development process, including whether the development of the compound subject to the CVR Agreement contemplated in connection

with the proposed transaction will be commercially successful, the risk that the expected benefits of the proposed transaction will not

be realized, potential litigation relating to the proposed transaction that could be instituted against the Company or its directors or

officers, including the effects of any outcomes related thereto, any competing offers or acquisition proposals for the Company, the possibility

that various conditions to the consummation of the proposed transaction may not be satisfied or waived and unanticipated difficulties

or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed

transaction, including with respect to the Company’s collaboration with Viatris, and/or potential difficulties in employee retention

as a result of the announcement and pendency of the proposed transaction, risks related to potential restructuring activities in connection

with the proposed transaction, including disruptions to the Company's recognition or utilization of certain tax attributes, factors that

could increase the Company’s expenses beyond its expectations and any factors that could adversely affect its profitability, whether

the TRELEGY milestone thresholds will be achieved, delays or difficulties in winding down clinical studies, risks of collaborating with

or relying on third parties to develop, manufacture and commercialize products, and risks associated with establishing and maintaining

sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, the ability of the

Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the

Company’s shares, and general economic and market conditions. Other risks affecting the Company are in the Company’s Form

10-Q filed with the SEC on May 7, 2026, and other periodic reports filed with the SEC. In addition to the risks described above and in

Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma’s results.

No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties,

you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking

statements on account of new information, future events or otherwise, except as required by law.

Page 5 of 9

Non-GAAP Financial Measures

Theravance Biopharma provides a non-GAAP metric in this press release.

Theravance Biopharma believes that non-GAAP net income (loss) provides meaningful information to assist investors in assessing prospects

for future performance and actual performance as they provide better metrics for analyzing the performance of its business by excluding

items that may not be indicative of core operating results and the Company's cash position. Because non-GAAP financial targets and metrics,

such as non-GAAP net income (loss), are not standardized, it may not be possible to compare these measures with other companies' non-GAAP

targets or measures having the same or a similar name. Thus, Theravance Biopharma's non-GAAP measures should be considered in addition

to, not as a substitute for, or in isolation from, the Company's actual GAAP results and other targets.

Please see the appendix attached to this press release for a reconciliation

of non-GAAP net income (loss) to its corresponding measure, net income (loss). A reconciliation of non-GAAP net income (loss) to its corresponding

GAAP measure is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential

variability of, expenses and other factors in the future.

Contact:

investor.relations@theravance.com

650-808-4045

Page 6 of 9

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

June 30,

December 31,

2026

2025

(Unaudited)

(1)

Assets

Current assets:

Cash and cash equivalents and short-term marketable securities

$ 387,657

$ 315,357

Receivables from collaborative arrangements

20,381

45,539

Receivables from milestone and royalty assets

50,000

Other prepaid and current assets

8,624

7,564

Total current assets

416,662

418,460

Long-term marketable securities

11,128

Property and equipment, net

5,169

5,895

Operating lease assets

21,926

24,371

Restricted cash

836

Other assets

25,177

24,880

Total assets

$ 469,770

$ 485,570

Liabilities and Shareholders' Equity

Current liabilities

$ 30,766

$ 38,302

Long-term operating lease liabilities

27,774

31,758

Future royalty payment contingency

32,795

Unrecognized tax benefits

88,486

85,679

Other long-term liabilities

244

313

Shareholders' equity

289,705

296,723

Total liabilities and shareholders’ equity

$ 469,770

$ 485,570

(1)  The condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

Page 7 of 9

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(Unaudited)

Revenue:

Viatris collaboration agreement (1)

$ 20,731

$ 18,695

$ 38,430

$ 34,083

Licensing revenue

7,500

Total revenue

20,731

26,195

38,430

41,583

Costs and expenses:

Research and development (2)

4,712

10,490

10,541

21,942

Selling, general and administrative (2)

14,176

18,430

31,896

36,800

Restructuring expenses (2) (3)

4,031

7,664

Transaction-related expenses

6,089

Total costs and expenses

29,008

28,920

56,190

58,742

Loss from operations

(8,277 )

(2,725 )

(17,760 )

(17,159 )

Net gain on realized contingent milestone and royalty assets

75,137

Interest expense (non-cash)

(663 )

(1,306 )

Interest income and other income, net

3,486

1,457

6,499

2,396

Income (loss) before income taxes

(4,791 )

73,206

(11,261 )

59,068

Provision for income tax (expense) benefit

(1,107 )

(18,371 )

430

(17,812 )

Net income (loss)

$ (5,898 )

$ 54,835

$ (10,831 )

$ 41,256

Net income (loss) per share:

Net income (loss) per share - basic

$ (0.11 )

$ 1.09

$ (0.21 )

$ 0.83

Net income (loss) per share - diluted

$ (0.11 )

$ 1.08

$ (0.21 )

$ 0.81

Shares used to compute net income (loss) per share - basic

51,667

50,177

51,474

49,943

Shares used to compute net income (loss) per share - diluted

51,667

50,726

51,474

50,685

Non-GAAP net income (loss)

$ 9,467

$ (4,225 )

$ 10,106

$ (12,843 )

(1)  While Viatris, Inc. records the total YUPELRI net sales, the Company is entitled to a 35% share of the net profit (loss) pursuant to a co-promotion agreement with Viatris as presented below:

Three Months Ended June 30,

Six Months Ended June 30,

(In thousands)

2026

2025

2026

2025

YUPELRI net sales (100% recorded by Viatris)

$ 70,666

$ 66,330

$ 133,097

$ 124,674

YUPELRI net sales (Theravance Biopharma implied 35%)

24,733

23,216

46,584

43,636

(2)  Amounts include share-based compensation expense as follows:

Three Months Ended June 30,

Six Months Ended June 30,

(In thousands)

2026

2025

2026

2025

Research and development

$ 566

$ 987

$ 1,193

$ 2,057

Selling, general and administrative

3,572

3,556

6,421

7,363

Restructuring expenses

1,852

2,880

Total share-based compensation expense

$ 5,990

$ 4,543

$ 10,494

$ 9,420

(3)  Restructuring expenses were comprised of:

Three Months Ended June 30,

Six Months Ended June 30,

(In thousands)

2026

2025

2026

2025

Cash-related expenses

$ 2,179

$ -

$ 4,784

$ -

Non-cash related expenses

1,852

2,880

Total restructuring expenses

$ 4,031

$ -

$ 7,664

$ -

Page 8 of 9

THERAVANCE BIOPHARMA, INC.

Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income (Loss)

(In thousands)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(Unaudited)

GAAP net income (loss)

$ (5,898 )

$ 54,835

$ (10,831 )

$ 41,256

Adjustments:

Licensing revenue (1)

(7,500 )

Net gain on realized contingent milestone and royalty assets (1)

(75,137 )

Share-based compensation expense

5,990

4,543

10,494

9,420

Non-cash interest expense

663

1,306

Income tax expense (benefit)

1,107

18,371

(430 )

17,812

Restructuring expense (excl. share-based compensation) (1)

2,179

4,784

Transaction-related expense (1)

6,089

Non-GAAP net income (loss)

$ 9,467

$ (4,225 )

$ 10,106

$ (12,843 )

(1)  Non-recurring item

Page 9 of 9

GRAPHIC

Filename: tm2622638d1_ex99-1img001.jpg · Sequence: 6

Binary file (11659 bytes)

Download tm2622638d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity File Number

001-36033

Entity Registrant Name

THERAVANCE

BIOPHARMA, INC.

Entity Central Index Key

0001583107

Entity Tax Identification Number

98-1226628

Entity Incorporation, State or Country Code

Entity Address, Address Line One

c/o Theravance Biopharma US, LLC

Entity Address, Address Line Two

901

Gateway Boulevard

Entity Address, City or Town

South

San Francisco

Entity Address, Country

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

808-6000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Ordinary

Share $0.00001 Par Value

Trading Symbol

TBPH

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration